Tango Therapeutics Inc
TNGX7.870USD
+0.250+3.28%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
872.56MMarket Cap
LossP/E TTM
More Details of Tango Therapeutics Inc Company
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
Company Info
Ticker SymbolTNGX
Company nameTango Therapeutics Inc
IPO dateSep 03, 2020
CEODr. Barbara Weber, M.D.
Number of employees155
Security typeOrdinary Share
Fiscal year-endSep 03
Address201 Brookline Avenue
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02215
Phone18573204900
Websitehttps://www.tangotx.com/
Ticker SymbolTNGX
IPO dateSep 03, 2020
CEODr. Barbara Weber, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Mr. Elizabeth Hickin
Mr. Elizabeth Hickin
Vice President, IR and Corporate Communications
Vice President, IR and Corporate Communications
--
--
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John Ketchum
Mr. John Ketchum
Independent Director
Independent Director
--
--
Mr. Kanishka Pothula
Mr. Kanishka Pothula
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
13.08%
TCG Crossover Management, LLC
9.65%
EcoR1 Capital, LLC
9.55%
Boxer Capital Management, LLC
8.78%
Farallon Capital Management, L.L.C.
8.23%
Other
50.70%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
13.08%
TCG Crossover Management, LLC
9.65%
EcoR1 Capital, LLC
9.55%
Boxer Capital Management, LLC
8.78%
Farallon Capital Management, L.L.C.
8.23%
Other
50.70%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.53%
Investment Advisor
36.01%
Investment Advisor/Hedge Fund
18.49%
Venture Capital
15.66%
Corporation
4.46%
Individual Investor
1.53%
Research Firm
0.73%
Family Office
0.64%
Bank and Trust
0.08%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
313
119.32M
107.84%
-16.77M
2025Q1
320
116.84M
107.85%
-22.33M
2024Q4
310
116.06M
107.37%
-22.45M
2024Q3
292
115.54M
108.00%
-9.29M
2024Q2
286
112.62M
105.54%
-13.62M
2024Q1
280
112.63M
105.80%
-9.88M
2023Q4
261
107.66M
105.42%
-11.67M
2023Q3
235
102.78M
102.09%
+4.42M
2023Q2
224
81.67M
92.47%
-10.11M
2023Q1
216
83.27M
94.51%
-3.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
16.86M
15.55%
-194.17K
-1.14%
Apr 01, 2025
TCG Crossover Management, LLC
10.74M
9.9%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
10.63M
9.81%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
10.38M
9.58%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
7.18M
6.63%
+2.57M
+55.76%
Jun 06, 2025
Nextech Invest, Ltd.
5.53M
5.11%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.74M
3.45%
-110.35K
-2.87%
Mar 31, 2025
Gilead Sciences Inc
4.85M
4.48%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
